Journal Section:
Retraction Statement

The article entitled “Regulation of iRhom-2/Tumor Necrosis Factor-α Converting Enzyme Pathway and Oxidative Stress Protects the Renal Injury with Anemonin in Streptozotocin-Induced Diabetic Nephropathy Neonatal Rat Model” [Pharmacology. 2019;104(5–6):258–66; DOI: 10.1159/000501631] by Lingyan Qiao, Yusheng Liu, Cheng Li, Juan Ge and Tang Li has been retracted by the Publisher and the Editor.

After the publication of this article, concerns were raised about the integrity of some of the data presented. Specifically, in Figure 5b the representative image for the Anemonin 75 mg/kg group was found to be partially duplicated in the representative image for the DN group in the same figure. A duplication between Figure 5a of this article and Figure 2a of a previously published article by a different author group was also found [1]. In addition, the images representing the TACE and β-Actin Western blots in Figure 4 of this article were found to be the same as the Western blots represented in Figure 5 of a previously published article by a different author group [2].

The authors did not respond to requests to comment on the concerns within the given timeframe despite multiple attempts of contact. The matter has been raised to the corresponding author’s institution who did not respond to our request for an investigation. Given the severity of the concerns raised this article is being retracted. The authors have not responded to our correspondence regarding this retraction despite multiple attempts of contact.

1.
Huang G, Lv J, Li T, Huai G, Li X, Xiang S, Wang L, Qin Z, Pang J, Zou B, Wang Y. Notoginsenoside R1 ameliorates podocyte injury in rats with diabetic nephropathy by activating the PI3K/Akt signaling pathway. Int J Mol Med. 2016;38(4):1179–89. DOI: 10.3892/ijmm.2016.2713.
2.
Ding Z, Shi H, Yang W. Osteoprotective Effect of Cimiracemate in Glucocorticoid-Induced Osteoporosis by Osteoprotegerin/Receptor Activator of Nuclear Factor κ B/Receptor Activator of Nuclear Factor Kappa-Β Ligand Signaling. Pharmacology. 2019;103(3–4):163–72. DOI: 10.1159/000495509.
© 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024